JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 8 December 2006. doi:10.1136/jcp.2006.041194
Journal of Clinical Pathology 2007;60:1086-1091
Copyright © 2007 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jcp.2006.041194v1
60/10/1086    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holm, R
Right arrow Articles by Nesland, J M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holm, R
Right arrow Articles by Nesland, J M
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Vulvar Cancer

ORIGINAL ARTICLES

Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis

R Holm1, S Knopp1, Z Suo1, C Tropè1,2, J M Nesland1

1 Department of Pathology, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway
2 Department of Gynecologic Oncology, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway

Correspondence to:
Dr Ruth Holm, Department of Pathology, Rikshospitalet-Radiumhospitalet Medical Center, Montebello, 0310 Oslo, Norway; ruth.holm{at}radiumhospitalet.no

Aims: To examine the expression of EphA2 and EphrinA-1 in vulvar squamous cell carcinomas and investigate their prognostic relevance.

Methods: Tumours from 224 patients with vulvar squamous cell carcinomas were investigated for expression of EphA2 and EphrinA-1 using single and double immunostaining methods.

Results: High expression (strong/moderate staining intensity) of EphA2 and EphrinA-1 was observed in 114 (51%) and 126 (56%) vulvar carcinomas, respectively. In the three cases tested using the double immunostaining method, colocalisation of EphA2 and EphrinA-1 proteins was identified in the same neoplastic cells. High EphA2 expression was significantly correlated to high expression of EphrinA-1 (p<0.01) and cyclin A (p<0.01), large tumour size (p = 0.03), deep invasion (p<0.01) and higher FIGO stage (p = 0.05). A correlation between high EphrinA-1 expression and high levels of cyclin A (p<0.01) and p21 (p<0.01), deep invasion (p<0.01) and higher FIGO stage (p = 0.01) was also seen. In univariate analysis, high expression of EphrinA-1 was associated with poor survival (p = 0.03). However, in the multivariate analysis neither EphrinA-1 nor EphA2 were significantly correlated to survival.

Conclusions: EphA2 and EphrinA-1 were overexpressed in 51% and 56% of the vulvar squamous cell carcinomas, respectively, and high levels of EphA2 and EphrinA-1 proteins were associated with deep tumour invasion and high FIGO stage. However, EphA2 and EphrinA-1 were not independently associated with clinical outcome in vulvar carcinomas.


Keywords: immunohistochemistry; vulvar cancer; EphA2; EphrinA-1




This article has been cited by other articles:


Home page
J. Clin. Pathol.Home page
R Holm, S Knopp, R Kumar, J Lee, J M Nesland, C Trope, and D F Callen
Expression of ZNF652, a novel zinc finger protein, in vulvar carcinomas and its relation to prognosis
J. Clin. Pathol., January 1, 2008; 61(1): 59 - 63.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.